Jefferies Downgrades Vistagen Therapeutics to Hold, Lowers Price Target to $0.9
Benzinga Newsdesk 11 months ago
NewsDowngradesPrice TargetAnalyst Ratings
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Jefferies analyst Andrew Tsai downgrades Vistagen Therapeutics (NASDAQ:VTGN) from Buy to Hold and lowers the price target from $15 to $0.9.
Jefferies analyst Andrew Tsai downgrades Vistagen Therapeutics (NASDAQ:VTGN) from Buy to Hold and lowers the price target from $15 to $0.9.